Verastem, Inc. (VSTM) Q2 2025 Earnings Call Transcript

2025-08-08 20:55:40 ET

Verastem, Inc. (VSTM)

Q2 2025 Earnings Conference Call

August 07, 2025, 04:30 PM ET

Company Participants

Daniel Calkins - Chief Financial Officer

Daniel W. Paterson - President, CEO & Director

Julissa Viana - Vice President of Corporate Communications & Investor Relations

Matthew E. Ros - Chief Operating Officer

Michael Crowther - Chief Commercial & Strategy Officer

Conference Call Participants

Anish Nikhanj - RBC Capital Markets, Research

Anqi Yu - Jefferies LLC, Research Division

Graig C. Suvannavejh - Mizuho Securities USA LLC, Research Division

Justin Reid Zelin - BTIG, LLC, Research Division

Michael Werner Schmidt - Guggenheim Securities, LLC, Research Division

Paul Jeng - Guggenheim Securities, LLC, Research Division

Pete George Stavropoulos - Cantor Fitzgerald & Co., Research Division

Sean Lee - H.C. Wainwright & Co, LLC, Research Division

Presentation

Operator

Thank you for standing by. My name is Rebecca, and I will be your conference operator today. At this time, I would like to welcome everyone to the Verastem Oncology Second Quarter 2025 Financial Results Conference Call. [Operator Instructions] Thank you. I will now turn the call over to Julissa Viana, Vice President, Corporate Communications, Investor Relations Patient Advocacy. Please go ahead.

Julissa Viana

Thank you, operator. Welcome, everyone, and thank you for joining us today to discuss Verastem's second quarter 2025 financial results and recent business updates. Earlier today, we issued a press release detailing our financial results for the second quarter of 2025. This release, along with a slide presentation that we will reference during our call today are available on our website....

Read the full article on Seeking Alpha

For further details see: